Small molecule PIKfyve inhibitors as cancer therapeutics: Translational promises and limitations
Author:
Funder
U.S. Department of Defense
Publisher
Elsevier BV
Subject
Pharmacology,Toxicology
Reference73 articles.
1. Network pharmacology for cancer drug discovery: are we there yet?;Azmi;Future Med. Chem.,2012
2. The phosphoinositide kinase PIKfyve promotes cathepsin-S-mediated major histocompatibility complex class II antigen presentation;Baranov;iScience,2019
3. Protein kinase B phosphorylation of PIKfyve regulates the trafficking of GLUT4 vesicles;Berwick;J. Cell Sci.,2004
4. PIKfyve/Fab1 is required for efficient V-ATPase and hydrolase delivery to phagosomes, phagosomal killing, and restriction of Legionella infection;Buckley;PLoS Pathog.,2019
5. Synthesis and in vitro and in vivo evaluation of phosphoinositide-3-kinase inhibitors;Burger;ACS Med. Chem. Lett.,2011
Cited by 45 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A PIKfyve modulator combined with an integrated stress response inhibitor to treat lysosomal storage diseases;Proceedings of the National Academy of Sciences;2024-08-16
2. Mechanism understanding of PIKfyve inhibitor YM201636 with human serum albumin: Insights from molecular modeling and multiple spectroscopic techniques;Luminescence;2024-07
3. Selective Termination of Autophagy-Dependent Cancers;Cells;2024-06-25
4. Why Certain Repurposed Drugs Are Unlikely to Be Effective Antivirals to Treat SARS-CoV-2 Infections;Viruses;2024-04-22
5. PIP4K2C inhibition reverses autophagic flux impairment induced by SARS-CoV-2;2024-04-17
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3